Modification of intracellular glutathione status does not change the cardiac trapping of Cu(ATSM) by unknown
Shaughnessy et al. EJNMMI Research 2014, 4:40
http://www.ejnmmires.com/content/4/1/40ORIGINAL RESEARCH Open AccessModification of intracellular glutathione status
does not change the cardiac trapping of 64Cu
(ATSM)
Fiona Shaughnessy1, Erika Mariotti1, Karen P Shaw1, Thomas R Eykyn1, Philip J Blower1, Richard Siow2
and Richard Southworth1*Abstract
Background: The trapping mechanisms of the PET hypoxia imaging agent copper(II)-diacetyl-bis
(N4-methylthiosemicarbazone) (64Cu(ATSM)) remain unresolved, although its reduction prior to dissociation may be
mediated by intracellular thiols. Glutathione (GSH) is the most abundant intracellular thiol, and its redox status changes
in cancer cells and ischaemic myocardium (two prime applications for 64Cu(ATSM) PET). We therefore investigated
whether modification of intracellular GSH content affects the hypoxia selectivity of 64Cu(ATSM).
Methods: Isolated rat hearts (n = five per group) were perfused with aerobic buffer (equilibrated with 95%O2/5%
CO2) for 15 min, then hypoxic buffer (95%N2/5%CO2) for 20 min. Cardiac glutathione was depleted by buthionine
sulphoximine (BSO, 4 mmol/kg/ 48 h intraperitoneal), or augmented by N-acetyl cysteine (NAC, 4 mmol/L) in the
perfusion buffer. Cardiac 64Cu retention from three 2-MBq bolus injections of 64Cu(ATSM) before and during
hypoxia was then monitored by NaI detectors.
Results: Cardiac GSH content was elevated by NAC and depleted by BSO (from 7.9 ± 2.0 to 59.3 ± 8.3 nmol/mg
and 3.7 ± 1.0 nmol/mg protein, respectively; p < 0.05). Hypoxia did not affect cardiac GSH content in any group.
During normoxia, tracer washed out bi-exponentially, with 13.1% ± 1.7% injected dose being retained; this was not
affected by GSH augmentation or depletion. Hypoxia significantly increased tracer retention (to 59.1% ± 6.3%,
p < 0.05); this effect was not modified by GSH augmentation or depletion.
Conclusion: Modification of GSH levels had no impact upon the pharmacokinetics or hypoxia selectivity of 64Cu
(ATSM). While thiols may yet prove essential for the intracellular trapping of 64Cu(ATSM), they are not the
determinants of its hypoxia selectivity.
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Radiocopper bis(thiosemicarbazone) complexes demon-
strate promise as hypoxia imaging agents, with potential
applications in oncology and cardiology. The lead com-
pound in this class, copper(II)-diacetyl-bis(N4-methyl-
thiosemicarbazone) (64Cu(ATSM)) has previously been
demonstrated to identify hypoxic regions in tumours
[1-4] and the myocardium [5-8] with high first pass* Correspondence: richard.southworth@kcl.ac.uk
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reproduction in any medium, provided the origuptake and rapid clearance from normoxic tissue. The
mechanism of its tissue retention, however, remains un-
clear [9,10]. It is currently thought that the lipophilic
complex, Cu(II)(ATSM), diffuses into the cell, whereupon
it is reduced intracellularly to Cu(I)-ATSM− [9,10]. Under
normoxic conditions, this unstable Cu(I)(ATSM)− species
is reoxidised to Cu(II)(ATSM) and leaves the cell. In
hypoxic tissue, however, there is insufficient oxygen to
reoxidise Cu(I)(ATSM), which dissociates, releasing its
radiocopper core to become trapped within the cell by
copper sequestering proteins. Although it is apparent that
hypoxia promotes radiocopper retention, the reductants
responsible for the initial reduction remain unidentified.his is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
inal work is properly credited.
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were capable of reducing 3-ethoxy-2-oxobutyraldehyde
bis(thiosemicarbazone) (Cu-KTS), leading to the sugges-
tion that intracellular thiols may be responsible for the
reduction of these complexes [11,12]. The antioxidant
glutathione (GSH) is the most abundant thiol-containing
species intracellularly, at an average intracellular concen-
tration of approximately 5 mmol/L [13]. Since intracellular
GSH status changes in numerous diseases (particularly
cardiac ischaemia and cancer [14-16]), such variation in
intracellular GSH-mediated reductive capacity may impact
upon 64Cu(ATSM) hypoxia selectivity and its potential
clinical usefulness.
We have recently described an isolated perfused heart
system coupled with a triple NaI gamma detection ap-
paratus which allows the characterisation of radiotracer
pharmacokinetics in an intact functioning organ over
which we have complete functional control [8,17]. This
approach allows us to perform reproducible interven-
tions (such as accurately titrated hypoxia) under condi-
tions which may otherwise be lethal in vivo and examine
tracer pharmacokinetics in a tissue of interest directly,
without the added complications of circulating tracer
metabolites which can frequently be problematic in vivo.
In this study, we have utilised this approach to deter-
mine whether depletion or augmentation of intracellular
GSH status impacts upon the pharmacokinetics or hyp-
oxia selectivity of 64Cu-ATSM.
Methods
Chemicals and reagents
DL-buthionine (S,R)-sulphoximine 99% (BSO), trichlo-
roacetic acid 6.5% and the bicinchoninic acid (BCA) assay
kit were obtained from Fisher Scientific (Loughborough,
UK). N-acetyl-L-cysteine 99% (NAC) and O-phthalaldehyde
(OPA) were obtained from Sigma-Aldrich (Dorset, UK).
64Cu(ATSM) synthesis
64Cu was provided by the PET imaging centre, St.
Thomas' Hospital, London. ATSM was labelled with
64Cu as described by Handley et al. [18].
Animals
Male Wistar rats (275 to 350 g) with ad libitum access
to food and water were used throughout. All experimen-
tal procedures were carried out in accordance with
Home Office regulations as detailed in the Guidance on
the Operation of Animals (Scientific Procedures) Act
1986.
GSH depletion/augmentation
GSH levels were depleted by pre-treating rats twice daily
for 2 days with intraperitoneal injections of BSO dis-
solved in 0.9% NaCl (total dose 4 mmol/kg body weight).Hearts were excised and Langendorff-perfused 24 h after
the final dose. In further groups of animals, the cardiac
GSH concentration was augmented by supplementing
the perfusion medium, (modified Krebs Henseleit buffer
(KHB), with NAC (4 mmol/L).
Heart perfusion
Rats were anaesthetised with sodium pentobarbitone
and heparinised (200 IU intraperitoneal). The hearts
were excised and placed immediately in KHB (4°C)
comprising NaCl (118 mmol/L), KCl (5.9 mmol/L),
MgSO4 (1.16 mmol/L), NaHCO3 (25 mmol/L), NaEDTA
(0.48 mmol/L), glucose (11.1 mmol/L) and CaCl2
(2.2 mmol/L) and then Langendorff-perfused at a con-
stant rate of 14 mL/min with KHB gassed with 95%
O2/5%CO2 at 37°C. To induce cardiac hypoxia, perfu-
sion was switched to KHB gassed with 95%N2/5%CO2.
Buffer oxygen saturation was monitored throughout each
experiment by an OxyLite™ fluorescent oxygen probe
(Oxford Optronix Ltd., Oxfordshire, UK) inserted into
the arterial perfusion line. Coronary perfusion pressure
was monitored via a pressure transducer mounted in the
arterial line. Cardiac contractile function was monitored
via a pressure transducer connected to a latex balloon
inserted into the left ventricle, inflated to give an end-
diastolic pressure of 4 to 9 mmHg. Coronary effluent was
collected at regular intervals and subsequently analysed
for lactate content using a 2300 STAT Plus™ lactate ana-
lyser (YSI Ltd., Hampshire, UK).
Perfusion protocols
All hearts were perfused with normoxic KHB for a sta-
bilisation period of 10 min to ensure cardiac contractile
function exclusion criteria were met before continuing
each experiment. The hearts were then perfused for a
further 45 min according to the protocols in Figure 1.
Three boluses of 64Cu(ATSM) (2 MBq in 100 μL KHB)
were injected into the arterial perfusion line after 10-
min normoxic perfusion and 5 and 25 min after the on-
set of hypoxia (or normoxic equivalent). A custom-built
triple detector system was used to measure cardiac 64Cu
retention and washout [8]. This comprised three orthog-
onally arranged lead collimated Na/I γ-radiation detec-
tors (Raytest Isotopenmessgeräte GmbH, Straubenhardt,
Germany) measuring 64Cu activity at the input (arterial)
perfusion line, the heart and the output perfusion line.
The detectors were connected to a Gina Star™ data acquisi-
tion system (Raytest Isotopenmessgeräte GmbH), and data
were acquired by Gina Star™ software (version 4.0.2.75).
Data were normalised to the maximum peak counts
after each injection and corrected for decay and cardiac
background activity 30 s prior to each injection [8]. Phar-
macokinetic analysis of time activity curve data was per-
formed using MATLAB® (version 7.11.0, MathWorks®,
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Figure 1 Perfusion protocols. Protocols are for hearts from all treatment groups and show timings of 64Cu(ATSM) bolus administration (arrows).
(A) Normoxic control with/without GSH depletion, (B) normoxic GSH augmented, (C) hypoxic control with/without GSH depletion and (D) hypoxic
GSH augmented groups.
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function:
f tð Þ ¼ ae−bt þ ce−dt
where b and d represent the slow and fast clearance
rate constants (SCR and FCR), and a and c are the
amplitudes assigned to these constants, respectively, as
described previously [8,17,19].
GSH measurement in heart tissue
At the end of each perfusion protocol, the hearts were
snap-frozen in liquid nitrogen and stored at −70°C. The
hearts were ground into a fine powder under liquid ni-
trogen using a steel pestle and mortar. Of this powder,





























Figure 2 Effect of (A) BSO pre-treatment and (B) NAC perfusion on m
(n = 5 per group). *p < 0.05 vs. untreated equivalents.extracted by adding 2.5 mL ice-cold trichloroacetic acid
for 20 min. The samples were centrifuged at 10,000 rpm
at 4°C for 10 min. The trichloroacetic acid supernatant
was then aspirated and analysed for GSH content using
the OPA fluorescence assay as described previously [20].
NaOH (2.5 mL, 1 mmol/L) was then added to the cell
pellet for 2 h, then aspirated and analysed for protein
content using a BCA assay kit [21].Statistical analysis
All data are presented as the mean ± standard deviation.
Statistical significance was evaluated using a one-way
ANOVA followed by Bonferroni post hoc test using
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yocardial GSH (SH) content. Data are expressed as means ± SD
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Effect of BSO and NAC on myocardial GSH concentration
BSO pre-treatment caused a significant depletion of
GSH concentration (from 7.9 ± 2.0 to 3.7 ± 1.0 nmol/mg
protein, p < 0.05, Figure 2). These values were not
affected by perfusion with hypoxic buffer (8.0 ± 1.7 and
3.3 ± 0.6 nmol/mg protein). Perfusion with NAC caused
a significant increase in GSH concentration (from 7.9 ±
2.0 to 59.3 ± 8.3 nmol/mg protein, p < 0.05), and these
values were also unaffected by perfusion with hypoxic
buffer (8.0 ± 1.7 and 67.1 ± 13.9 nmol/mg protein). The
perfusion of hearts with hypoxic buffer had no effect on
cardiac GSH status in any group.
Myocardial uptake of 64Cu from 64Cu(ATSM) during
normoxia and hypoxia
Buffer oxygen saturation at the perfusion cannula fell
from >100 to <20 mmHg within 5 min and to <5 mmHg
within 20 min of switching to hypoxic buffer, and left
ventricular developed pressure fell from 129.3 ± 16.8 to
53.0 ± 15.3 mmHg within 5 min to 0 mmHg after
20 min (Figure 3) [8]. Lactate release peaked at 0.4 ±
0.07 nmol/mL dry weight tissue after 3 min of switching
to hypoxic buffer, before declining as contractility de-
creased (Figure 4). Neither GSH depletion nor augmen-
tation affected developed pressure or lactate release
during perfusion with normoxic or hypoxic buffer. Figure 5
displays representative traces from the second Na/I
detector, monitoring cardiac 64Cu radiotracer uptake
and washout. During normoxic perfusion, 13.1% ± 1.7%
of the injected dose (ID) remained in the heart 20 min
after the first injection. This did not significantly differ
in subsequent injections (Figure 6A). Neither GSH
augmentation nor GSH depletion had any effect on
cardiac 64Cu retention during normoxic perfusion. Per-
fusion of hearts with hypoxic buffer caused a signifi-
cant increase in tracer retention to 45.6% ± 5.8% ID
after 5 min and further still to 59.1% ± 6.3% ID after
25 min (Figure 6B). Neither depletion nor augmenta-
tion of GSH affected this hypoxia-dependent retention
(11.2% ± 2.6% to 13.2% ± 4.6% in GSH-depleted and
46.5% ± 5.5% to 51.3% ± 12.1% in GSH-augmented
hearts).
64Cu(ATSM) pharmacokinetics
Using non-linear spectral analysis, we determined that
cardiac tracer washout was biphasic, with fast and slow
components [17]. The FCR (d) of tracer from normoxic
hearts was consistent throughout the perfusion protocol
and was unaffected by either GSH augmentation or de-
pletion. There was no difference in FCR in hearts from
normoxic control, GSH-depleted or GSH-augmented
protocols across all injections (Table 1). Similarly, there
was no difference in SCR from these hearts. Theamplitude of the FCR and SCR, c and a respectively,
also did not differ between different injections or different
treatment groups under normoxic conditions (Table 2).
The c values were significantly higher than a in all
hearts under normoxic conditions.
Hypoxia caused a progressive increase in the FCR, and
a decrease in the SCR, becoming significantly different
from normoxic values in all groups by 25 min of hypoxia
(Table 1). None of these rates were affected by either
GSH augmentation or GSH depletion. During normoxia
in non-GSH-modified hearts, the amplitude of the FCR
was 0.7 ± 0.02, and the amplitude of the SCR was 0.2 ±
0.03. This was not affected by GSH modification. After
25 min hypoxia, the amplitude of the FCR fell to 0.2 ±
0.03, while the amplitude of the SCR increased to 0.7 ±
0.05 (p < 0.05). These changes in respective amplitudes
were not altered by modification of cardiac GSH status.Discussion
We have demonstrated that depletion or augmentation
of GSH status to degrees matching or exceeding those
measured in cardiovascular disease or cancer had no effect
on the retention of 64Cu(ATSM) or its pharmacokinetic
profile under either hypoxic or normoxic conditions. Fur-
thermore, we have shown that inducing sufficient hypoxia
to cause a significant increase in 64Cu trapping from 64Cu
(ATSM) causes no measurable change in intracellular
GSH status, at least in this acute experimental setting.
Changes in intracellular GSH status within the limits of
this study therefore do not appear to affect the hypoxia se-
lectivity of 64Cu(ATSM), as had previously been suggested
[10]. In 1972, Petering reported that thiols directly reduce
Cu-KTS; however, little has since been reported on the
GSH-mediated reduction of Cu(ATSM) [11]. GSH has
more recently been demonstrated incapable of reducing
Cu(ATSM) in an in vitro system [22]; however, this study
did not preclude GSH acting as a cofactor in the (possibly
enzymatic) reduction of the tracer inside the cell, nor did
it replicate the relative concentrations of tracer and thiol
that would occur in vivo; to quantify Cu(ATSM) spec-
trophotometrically, it was necessary for Xiao et al. to
use concentrations of Cu(ATSM) many orders of mag-
nitude higher than we used in our experiments, which
are closer to those occurring in vivo during a PET scan.
While BSO pre-treatment has previously been shown
to not affect Cu(ATSM) retention in neuroblastoma
cells under normoxic conditions, intracellular GSH
concentrations in these experiments were not quanti-
fied, making it difficult to draw a definitive conclusion
[23]. In our study, therefore, we employed a sensitive
radiometric technique allowing us to investigate Cu
(ATSM) pharmacokinetics at tracer concentrations in
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Figure 3 Left ventricular developed pressure (mmHg) for hearts from all perfusion protocol groups. Data are expressed as means ± SD
(n = 5). (A) Normoxia control, (B) hypoxia, (C) normoxia + BSO, (D) hypoxia + BSO, (E) normoxia + NAC, (F) hypoxia + NAC.

































































































0                     20              40                    60
Time (mins)
0.0












0        20                    40                    60
Time (mins)
0.0













0                     20                    40                    60
Time (mins)
0.0







Figure 4 Cardiac lactate release. Lactate concentration was measured in perfusate samples collected from isolated perfused hearts. Data are
expressed as means ± SD (n = 5). (A) Normoxia control, (B) hypoxia, (C) normoxia + BSO, (D) hypoxia + BSO, (E) normoxia + NAC, (F) hypoxia + NAC.
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Figure 5 Representative time-activity curves demonstrating 64Cu retention from 64Cu(ATSM) in (A) normoxic and (B) hypoxic hearts.
Curves represent untreated hearts (top), GSH depleted hearts (centre) and GSH augmented hearts (bottom).
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Figure 6 Effect of GSH concentration on cardiac 64Cu retention from 64Cu(ATSM). 64Cu retention was measured in GSH depleted (BSO) and
augmented (NAC) hearts during (A) normoxia and (B) hypoxia. Data are expressed as the percentage of total activity injected (means ± SD, n = 5
per group). *p < 0.05 vs. normoxia (injection 1), #p < 0.05 vs. early hypoxia (injection 2) and †p < 0.05 vs. late hypoxia alone (injection 3).
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intracellular GSH concentrations.
Intracellular GSH status changes dramatically during
many disease processes in response to increased oxida-
tive stress. In the heart, atrial glutathione levels have
been demonstrated to be 58% lower in NYHA class IV
patients than in healthy subjects [14]. Experimentally, inisolated perfused rabbit hearts, the total GSH content
fell by 54% after 90 min of ischaemia and by 61% 30 min
after reperfusion. These degrees of GSH depletion are
comparable to those we observe following BSO treat-
ment in our model. The GSH content of cancer cells is,
perhaps unsurprisingly, more variable. While adenocar-
cinomas and large cell carcinomas have been shown to
Table 1 Effect of GSH concentration on the fast and slow clearance rates of 64Cu(ATSM)
Clearance rate Type of heart Injection Untreated BSO NAC
FCR (kd (min
−1)) Normoxic hearts Normoxia 1.2 ± 0.2 1.1 ± 0.1 1.3 ± 0.2
Normoxia 1.1 ± 0.2 1.1 ± 0.2 1.4 ± 0.1
Normoxia 1.2 ± 0.1 1.2 ± 0.2 1.4 ± 0.4
Hypoxic hearts Normoxia 1.2 ± 0.2 1.1 ± 0.2 1.2 ± 0.2
Early hypoxia 1.9 ± 0.4 1.8 ± 0.5 1.9 ± 0.3
Late hypoxia 2.5 ± 0.6* 2.2 ± 0.5* 2.2 ± 0.8*
SCR (kb (min
−1)) Normoxic hearts Normoxia 0.01. ± 0.002 0.008 ± 0.002 0.01 ± 0.006
Normoxia 0.01 ± 0.002 0.01 ± 0.008 0.01 ± 0.006
Normoxia 0.01 ± 0.002 0.01 ± 0.004 0.01 ± 0.004
Hypoxic hearts Normoxia 0.01 ± 0.007 0.01 ± 0.002 0.01 ± 0.002
Early hypoxia 0.007 ± 0.005 0.008 ± 0.005 0.009 ± 0.002
Late hypoxia 0.003 ± 0.003* 0.004 ± 0.002* 0.005 ± 0.002*
The effect of GSH supplementation (with NAC) and GSH depletion (with BSO) upon the fast clearance rate (FCR) and slow clearance rate (SCR) of 64Cu(ATSM) in
normoxic and hypoxic hearts. Data represent means ± SD, n = 5 per group, *p < 0.05 vs. normoxic equivalent.
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lung tissue, squamous cell carcinomas contain 207% of
control values [24]. The drug resistance of many tumours
is thought to be mediated in part by GSH levels elevated
up to 50-fold greater than normal [25-27]. With such large
variations in intracellular GSH status in these disease pro-
cesses, which 64Cu(ATSM) purportedly targets by virtue
of their hypoxic status, it is essential to confirm that this
hypoxia selectivity is not affected by variations in intracel-
lular GSH content. While our results suggest that changes
in GSH concentration do not contribute to the hypoxia
selectivity of 64Cu(ATSM), we are not proposing that
64Cu(ATSM) reduction is not GSH-mediated. While it
is still possible that other reductants may be responsible
for this process (and that they may change during hyp-
oxia to cause increased tracer retention), the intracellularTable 2 Effect of GSH concentration on the amplitudes of fas
Amplitude of clearance rate Type of heart Injecti












The effect of GSH supplementation (with NAC) and GSH depletion (with BSO) upon
of 64Cu(ATSM) in normoxic and hypoxic hearts. Data represent means ± SD, n = 5 peconcentration of GSH in mammalian cells is millimolar,
and in vast excess to the sub-nanomolar intracellular
concentration of 64Cu(ATSM) present when injected as
a PET tracer. As such, even the significant augmenta-
tion and depletion of intracellular GSH content that we
achieve in our experiments does not impact meaning-
fully upon this ratio. Intracellular thiols remain likely
candidates fundamental to the intracellular reduction of
64Cu(ATSM), but their high relative concentration means
that GSH-mediated 64Cu(ATSM) reduction is not a rate-
limiting factor in radiotracer retention. It is currently
unclear whether the rate of reduction or dissociation
may change during hypoxia, perhaps influenced by
changes in intracellular pH [9,10,28], or whether the
rate of tracer retention is purely governed by intracellu-
lar oxygen availability for reoxidation.t and slow clearance rates of 64Cu(ATSM)
on Untreated BSO NAC
xia 0.7 ± 0.02 0.8 ± 0.07 0.7 ± 0.07
xia 0.6 ± 0.04 0.7 ± 0.07 0.6 ± 0.04
xia 0.6 ± 0.04 0.6 ± 0.1 0.6 ± 0.06
xia 0.8 ± 0.04 0.8 ± 00.07 0.8 ± 0.04
ypoxia 0.4 ± 0.06 0.4 ± 0.06 0.4 ± 0.05
poxia 0.2 ± 0.03 0.2 ± 0.06 0.2 ± 0.03
xia 0.2 ± 0.03* 0.2 ± 0.04* 0.2 ± 0.03*
xia 0.3 ± 0.04* 0.2 ± 0.04* 0.3 ± 0.05*
xia 0.3 ± 0.03* 0.3 ± 0.05* 0.4 ± 0.04*
xia 0.2 ± 0.04* 0.2 ± 0.04* 0.2 ± 0.02*
ypoxia 0.5 ± 0.1 0.5 ± 0.02 0.5 ± 0.06
poxia 0.7 ± 0.05* 0.7 ± 0.05* 0.7 ± 0.05*
the amplitudes of the fast clearance rate (FCR) and slow clearance rate (SCR)
r group, *p < 0.05 vs. FCR.
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Copper bis(thiosemicarbazone) complexes represent a ver-
satile family of hypoxia imaging agents with a range of
hypoxia selectivities for a variety of applications in both
cardiology and oncology. To optimise the diagnostic and
prognostic insight gained from the PET images with these
complexes, it is essential to understand the nature of their
tissue uptake and retention. Here, we demonstrate that
their uptake is not sensitive to changes in intracellular
GSH concentration within the range investigated and pro-
vide further confirmation of their specificity for tissue
which is insufficiently oxygenated.
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